MED12 and neoplasm: Recent studies have shown that MED12 mutations, the most common leiomyoma alterations, are associated with tumor characteristics such as tumor size and number of tumors, as well as with treatment response to gonadotropin-releasing hormone agonists and ulipristal acetate [20–24].